University of Virginia School of Medicine scientists have developed an approach to drug development and discovery that could dramatically accelerate the creation of new medicines.
One of the greatest challenges in cancer immunotherapy is finding the rare immune cells, called tumor-reactive T cells, whose job it is to recognize and eliminate tumor cells.
